个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhou Caicun[1,*1] * ; Chen Gongyan[2] ; Huang Yunchao[3] ; Zhou Jianying[4] ; Lin LiZhu[5] ; Feng Jifeng[6] ; Wang Zhehai[7] ; Shu Yongqian[8] ; Shi Jianhua[9] ; Hu Yi[10] ; Wang QiMing[11] ; Cheng Ying[12] ; Wu Fengying[1] ; Chen Jianhua[13] ; Lin Xiaoyan[14] ; Wang Yongsheng[15] ; Huang Jianan[16] ; Cui Jiuwei[17] ; Cao Lejie[18] ; Liu Yunpeng[19] ; Zhang Yiping[20] ; Pan Yueyin[21] ; Zhao Jun[22] ; Wang LiPing[23] ; Chang Jianhua[24] ; Chen Qun[25] ; Ren Xiubao[26] ; Zhang Wei[27] ; Fan Yun[20] ; He Zhiyong[28] ; Fang Jian[29] ; Gu Kangsheng[30] ; Dong XiaoRong[31] ; Jin Faguang[32] ; Gao Hongjun[33] ; An Guangyu[34] ; Ding Cuimin[35] ; Jiang Xiaodong[36] ; Xiong Jianping[37] ; Zhou Xiangdong[38] ; Hu Sheng[39] ; Lu Ping[40] ; Liu Anwen[41] ; Guo Shuliang[42] ; Huang Jianjin[43] ; Zhu Chengchu[44] ; Zhao Jian[45] ; Gao Beili[46] ; Chen Yinglan[47] ; Hu Chengping[48] ; Zhang Jian[49] ; Zhang Hongmei[50] ; Zhao Hui[51] ; Tai Yanfei[52] ; Ma Xinjing[52] ; Shi Wei[52] ; on behalf of CameL Study Group[1] ;
机构： [1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China [2]Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China [3]Department of Thoracic Surgery Oncology, Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, People’s Republic of China [4]Respiratory Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China [5]Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China [6]Department of Thoracic Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People’s Republic of China [7]Department of Respiratory, Shandong Cancer Hospital & Institute, Jinan, People’s Republic of China [8]Department of Oncology, Jiangsu Province Hospital, Nanjing, People’s Republic of China [9]Department of Medical Oncology, Linyi Cancer Hospital, Linyi, People’s Republic of China [10]Oncology Department, General Hospital of Chinese People’s Liberation Army, Beijing, People’s Republic of China [11]Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, People’s Republic of China [12]Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, People’s Republic of China [13]Department of Medical Oncology-Chest, Hunan Cancer Hospital, Changsha, People’s Republic of China [14]Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China [15]Department of Thoracic Medical Oncology, West People’s Republic of China Hospital, Sichuan University, Chengdu, People’s Republic of China [16]Department of Respiration, First Affiliated Hospital of Suzhou University, Suzhou, People’s Republic of China [17]Department of Medical Oncology, The First Bethune Hospital of Jilin University, Changchun, People’s Republic of China [18]Pulmonary and Critical Care Medicine, The First Affiliated Hospital University of Science Technology of People’s Republic of China, Hefei, People’s Republic of China [19]Department of Medical Oncology, The First Hospital of People’s Republic of China Medical University, Shenyang, People’s Republic of China [20]Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China [21]Department of Tumor Chemotherapy, The First Affiliated Hospital University of Science Technology of People’s Republic of China, Hefei, People’s Republic of China [22]Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China [23]Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China (Prof L Wang MD) [24]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China [25]Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, People’s Republic of China [26]Department of Biotherapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People’s Republic of China [27]Pneumology Department, The First Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China [28]Department of Thoracic Oncology, Fujian Cancer Hospital, Fuzhou, People’s Republic of China [29]Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China [30]Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China [31]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China [32]Department of Respiratory Medicine, The Second Affiliated Hospital of Air Force Medical University, Xi'an, People’s Republic of China [33]Department of Pulmonary Oncology, Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, People’s Republic of China [34]Department of Medical Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China [35]Department of Respiratory Medicine, The Fourth Clinical Medical College of Hebei Medical University, Shijiazhuang, People’s Republic of China [36]Department of Medical Oncology, First People's Hospital of Lianyungang City, Lianyungang, People’s Republic of China [37]Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China [38]Department of Respiratory Medicine, First Affiliated Hospital of Army Medical University, Chongqing, People’s Republic of China [39]Department of Thoracic Medicine, Hubei Cancer Hospital, Wuhan, People’s Republic of China [40]Department of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, People’s Republic of China [41]Department of Medical Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China [42]Department of Respiratory Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China [43]Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China [44]Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Taizhou, People’s Republic of China [45]Department of Thoracic Surgical Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, People’s Republic of China [46]Department of Respiratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China [47]Department of Medical Oncology, Jiangxi Cancer Hospital, Nanchang, People’s Republic of China [48]Department of Respiratory Medicine, Xiangya Hospital Central South University, Changsha, People’s Republic of China [49]Department of Respiratory Medicine, The First Affiliated Hospital of Air Force Medical University, Xi'an, People’s Republic of China [50]Department of Medical Oncology, The First Affiliated Hospital of Air Force Medical University, Xi'an, People’s Republic of China [51]Department of Respiratory Medicine, Second Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China [52]Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, People’s Republic of China
出处：
DOI： 10.1016/j.jtho.2022.12.017
ISSN：

关键词： Immunotherapy PD-1 Camrelizumab Chemotherapy non-squamous non–small-cell lung cancer

摘要：
In CameL phase 3 study (ClinicalTrials.gov, NCT03134872), addition of camrelizumab to first-line chemotherapy significantly improved the progression-free survival in patients with stage IIIB-IV non-squamous NSCLC. Here, we present outcomes after a minimum follow-up of 43.9 months since last patient randomization.Eligible patients were randomized 1:1 to 4-6 cycles of camrelizumab plus carboplatin and pemetrexed or chemotherapy alone every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only (n=205 and 207, respectively). Total camrelizumab exposure was up to 2 years.As of January 31, 2022, camrelizumab plus chemotherapy exhibited substantially improved overall survival over chemotherapy alone (median, 27.1 versus 19.8 mo; hazard ratio, 0.72 [95% CI, 0.57-0.92]). In the chemotherapy alone group, 95 (45.9%) patients crossed over to camrelizumab monotherapy. After adjustment for crossover, the survival benefit with camrelizumab plus chemotherapy was more pronounced (adjusted hazard ratio, 0.55 [95% CI, 0.42-0.71]). In camrelizumab plus chemotherapy group, 33 patients completed 2 years of camrelizumab. Objective response rate was 97.0%, with ongoing responses in 17 of the 32 responses (53.1%); and 93.9% (31/33) of patients were alive at data cutoff. Safety profiles were consistent with the previous report, and no obvious evidence of cumulative toxicity was found with long exposure to camrelizumab.Camrelizumab plus carboplatin and pemetrexed provides long-term survival benefit over chemotherapy, with manageable toxicity, as well as remarkable and durable response in patients receiving 2 years of camrelizumab, further supporting camrelizumab combination as first-line treatment for advanced non-squamous NSCLC.Copyright © 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China [*1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507, Zhengmin Road, Shanghai 200433, People’s Republic of China
通讯作者：
通讯机构： [1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China [*1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507, Zhengmin Road, Shanghai 200433, People’s Republic of China
推荐引用方式(GB/T 7714)：
Zhou Caicun,Chen Gongyan,Huang Yunchao,et al.Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(5):628-639.doi:10.1016/j.jtho.2022.12.017.
APA：
Zhou Caicun,Chen Gongyan,Huang Yunchao,Zhou Jianying,Lin LiZhu...&on behalf of CameL Study Group.(2023).Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial.JOURNAL OF THORACIC ONCOLOGY,18,(5)
MLA：
Zhou Caicun,et al."Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial".JOURNAL OF THORACIC ONCOLOGY 18..5(2023):628-639

相关文献

[1]Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. [2]Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study [3]First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial [4]A Study of Atezolizumab Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer [5]Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy [6]Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer [7]Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial [8]NETWORK META-ANALYSIS OF EFFICACY OF PEMETREXED- OR BEVACIZUMAB-BASED REGIMENS IN FIRST-LINE AND MAINTENANCE TREATMENT FOR ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER [9]A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [10]Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study.

资源点击量：52808 今日访问量：1 总访问量：4560 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号